Table 2 Univariate survival analysis in patients

Preoperative PSA (ng/ml)

0.504

0.031

 ≤ 20

67.2 (55.5–72.1)

67.8 (60.7–73.2)

 > 20

64.4 (58.6–71.0)

59.9 (55.3–69.6)

Gleason score^a

0.066

0.015

 ≤ 6

Not reached

Not reached

7

67.8 (62.6–68.4)

63.7 (59.3–66.6)

 ≥ 8

64.1 (57.1–65.6)

50.0 (39.4–57.8)

Therapeutic methods

0.391

0.352

Neo CAB + Post ADT

Not reached

62.5 (57.2–70.1)

Neo CAB + Post ADT + Post Che

71.3 (68.8–73.2)

64.3 (53.0–67.4)

Neo CAB + Post ADT + Post Rad

66.9 (64.3–70.1)

61.7 (58.2–65.7)

Neo Che + Post ADT + Post Che

67.9 (63.5–69.5)

65.0 (63.8–72.5)

Local lymph node status^a

0.036

0.219

pN0

72.2 (68.8–74.5)

68.4 (62.2–69.9)

pN1

64.3 (61.1–67.0)

69.4 (65.7–72.6)

Seminal vesicle status^a

0.406

0.266

Negative

71.3 (67.7–72.7)

70.3 (66.2–72.3)

Positive

68.6 (65.6–71.0)

69.8 (64.0–71.7)

Surgical margins^a

0.338

0.014

Negative

70.6 (66.7–71.9)

70.2 (65.4–72.8)

Positive

68.8 (67.2–69.6)

59.7 (57.8–66.3)

Invasion depth of bladder wall^a

0.021

0.038

Non-muscle-invasion

68.8 (65.9–73.0)

Not reached

Muscle-invasion

61.5 (54.2–68.1)

60.4 (55.6–67.1)